Levulan

Quick links to important sections

Levulan

Treatment option: Keratoses

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levulan

Property Description
Active Ingredient Aminolevulinic Acid (\delta-Aminolevulinic Acid)
Form Topical Solution
Pharmacological Class Photodynamic Therapy (PDT) Agent
General Purpose Localized skin treatment requiring light activation
Origin/Type Synthetic Exogenous Precursor

What is Levulan and its Active Ingredient?

Levulan is a prescription medication whose active substance is Aminolevulinic Acid (ALA), primarily categorized as a Photodynamic Therapy (PDT) Agent. This compound is a synthetic exogenous precursor, meaning it is manufactured externally and applied to the body to initiate a complex biological process.

Aminolevulinic Acid acts as a precursor to the potent photosensitizer Protoporphyrin IX (PpIX). This means the drug's effect relies on its ability to be converted into the light-sensitive compound once inside the cells. Levulan is notable as a single-agent product delivered in an alcohol-based solution, a formulation specifically designed for clear, targeted topical application. Its role is unique among dermatological agents, functioning not as a direct treatment, but as an essential chemical primer for a subsequent light-based procedure.

The Form and General Therapeutic Purpose of Levulan

Levulan is supplied as a Topical Solution and is strictly designed for Topical (Cutaneous) administration, confirming its identity as a non-systemic agent. The general therapeutic purpose of this drug is to facilitate the highly selective and localized management of certain dermatological conditions in adult patients.

Because the medication is applied directly to the skin, the formulation is designed to minimize absorption into the rest of the body, thus localizing its effect. The use of Aminolevulinic Acid allows for the induction of a cytotoxic effect that is limited to the targeted area due to the requirement of light activation. This principle ensures the action is tightly controlled and focused. The general purpose is achieved through its mechanism as a photosensitizer precursor: it causes Protoporphyrin IX (PpIX) Accumulation within specific target cells, chemically "tagging" them and making them uniquely sensitive to light exposure.

What side effects are possible with Levulan?

Possible Side Effects and Safety Information

The official safety profile for Aminolevulinic Acid (Levulan) is primarily characterized by localized adverse reactions resulting from the photodynamic process. Adverse events are grouped by frequency and the body system affected, according to regulatory standards from the U.S. Food and Drug Administration (FDA) and similar global authorities.


Adverse Reaction Classifications

Adverse reactions are overwhelmingly classified as local application site reactions (Skin and Subcutaneous Tissue Disorders). These include, but are not limited to, erythema (redness), edema (swelling), stinging/burning, scaling, and crusting. The application site reactions are considered very common, meaning they occur in 10% or more of treated patients.

Less frequent but documented adverse reactions involve the Nervous System (e.g., headache) and General Disorders, such as chills or fever. Rare but serious safety considerations noted in regulatory post-marketing surveillance include transient amnestic episodes (temporary memory problems) following blue light exposure.


Safety Restrictions and Contextual Patterns

The label specifies that the treated skin becomes highly photosensitive for 40 hours after the product application, defining a critical time-related safety pattern. Patients with a history of Porphyria (acute or chronic types) are strictly contraindicated from using the medication due to the high risk of severe phototoxicity.

Furthermore, the safety and effectiveness of Levulan have not been established in pediatric patients (under 18). Use is restricted in patients with known hypersensitivity to the drug or its components. Caution is also noted when used alongside other medications that are known photosensitizing agents, which may increase the severity of local skin reactions.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Levulan (Aminolevulinic Acid Topical Solution) is defined by regulatory authorities primarily as an event of over-application or overexposure to light following the product's use.


Documented Overdose Manifestations

An overdose is typically presented as an exaggerated local reaction at the site of application. Manifestations documented in the official labeling include severe photosensitivity, which may lead to intense local stinging, burning, severe redness (erythema), and swelling (edema). This presentation primarily affects the dermatological system.


Regulatory-Mandated Emergency Actions

The primary required action to prevent or manage overexposure is strict adherence to the photoprotection protocol. The label mandates that treated areas must be protected from sunlight and all bright indoor light sources for at least 40 hours. In the event of accidental ingestion of the topical solution, immediate medical attention is required, and patients should contact emergency services or a poison control center.


Supportive Measures and Antidote Information

Regulatory guidance states that the management of overdose is strictly symptomatic and supportive. This involves protecting the patient from light exposure until the local reactions have subsided. Furthermore, regulatory documentation explicitly states that no specific antidote is known for Aminolevulinic Acid overdose.

Therapeutic Uses of Levulan

What Levulan Treats: Main Uses and Benefits for Skin Health

Levulan Photodynamic Therapy (PDT) is generally used for certain skin conditions associated with sun damage. Its main use is in managing rough, scaly lesions and may assist with improving the skin's appearance. The combination is indicated for the treatment of minimally to moderately thick actinic keratoses (AKs) on the face, scalp, or upper extremities.


Managing Pre-Cancerous Skin Patches

Levulan is generally used for conditions associated with actinic keratoses (AKs), which are sun-damaged lesions. This treatment helps address symptom clusters that may become intense or disruptive, such as the visible and palpable rough texture, scaly patches, and physical discomfort associated with these lesions. The therapy contributes to easing the overall symptom load.

“Applied across domains where additional symptomatic support is needed.”

Quick Fact: Support for Sun-Damaged Lesions The therapy may assist with managing these growths, contributing to supportive lesion management during periods of heightened symptoms.


Improving Overall Skin Appearance

The treatment is relevant for addressing the symptomatic burden of conditions characterized by periods of heightened symptoms. It is applied when symptoms create noticeable interference with the skin's smooth appearance and overall functional stability. Patients may generally experience an improved cosmetic response, which helps maintain a sense of stability and supports clearer-looking skin following periods of heightened symptoms.

Eligibility and Restrictions for Use

Levulan (aminolevulinic acid HCl) eligibility is strictly defined by regulatory documents, focusing on patient age and underlying medical conditions that conflict with the drug's photosensitizing nature.

Populations for Whom Use is Contraindicated

Use is contraindicated in patients with:

  • Porphyria or known allergies to porphyrins.
  • Known sensitivity to the active ingredient or any solution component.
  • Cutaneous photosensitivity at blue light wavelengths (400-450 nm).

Age-Related Eligibility and Restrictions

Age Group Eligibility Status
Pediatric (<18 years) Safety and effectiveness have not been established.
Adult (ge 18 years) Eligible under standard labeled conditions.
Geriatric (ge 65 years) Allowed; no overall difference in safety or effectiveness observed.

Special Population Status

  • Coagulation Defects: Caution is required, as the product has not been tested in patients with inherited or acquired blood clotting problems.
  • Pregnancy/Lactation: Insufficient data are available from the official labeling to inform a drug-associated risk for pregnant or breastfeeding women.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Aminolevulinic Acid Topical Solution is primarily defined by a single pharmacodynamic interaction involving light sensitivity, reflecting its use as a Photodynamic Therapy (PDT) agent. Due to its topical route of administration and minimal systemic absorption, the official regulatory labeling confirms the absence of documented interactions affecting drug metabolism or clearance, such as those involving cytochrome P450 (CYP) enzymes or drug transporters.

Documented Pharmacodynamic Interactions

Co-administration or recent use of other topical or systemic medicinal products known to cause photosensitivity may result in an additive phototoxic effect. This interaction can increase the severity of the expected phototoxicity associated with the PDT procedure. The official regulatory documents list specific drug classes that have the potential for this interaction, necessitating consideration before treatment.

Interaction Type Interacting Product Categories (Examples)
Additive Photosensitivity Tetracyclines, Sulfonamides, Phenothiazines
Sulfonylureas, Diuretics, Griseofulvin

Absence of Pharmacokinetic Interactions

No restrictions or requirements are documented in the official regulatory sources concerning interactions based on altered clearance, metabolism, or reduced exposure of Levulan or other co-administered systemic medicinal products. Furthermore, no specific interactions with food, alcohol, or herbal products are officially documented in the interaction section of the labeling.

Mechanism of Action

Targeted Cellular Precursor Uptake and Conversion

This initial phase of the mechanism involves the drug being preferentially absorbed and metabolized by specific cells in the tissue. Once inside, it enters the Heme Biosynthesis Pathway, where it is converted into the highly photosensitive compound, Protoporphyrin IX (PpIX). This targeted metabolic conversion contributes to the concentration of the active agent in situ and limits the mechanism of action primarily to the target tissue.


Light-Triggered Photosensitization and ROS Generation

The mechanism transitions to its activation phase when the accumulated PpIX is exposed to a specific wavelength of light. The PpIX absorbs this energy and transfers it to surrounding oxygen molecules, leading to the rapid and massive production of highly reactive and destructive Reactive Oxygen Species (ROS), primarily singlet oxygen (^1O2). This light-triggered generation of highly reactive free radicals initiates the subsequent cellular damage.


Oxidative Damage and Tissue Clearance

The generated ROS immediately inflict irreversible oxidative stress on essential cellular components, including membranes and mitochondria, causing rapid, localized cellular destruction (cytotoxicity). This localized, non-specific cellular damage leads to the clearance of the affected cells and the subsequent initiation of the body's natural tissue repair processes.

Dosage and Administration Information

How Levulan Photodynamic Therapy is Used

Levulan Photodynamic Therapy (PDT) is a two-stage procedure that is strictly administered in a clinical setting by a qualified healthcare professional. The medication is a 20% topical solution that is not intended for patient self-application.

Official Administration and Dosage Protocol

The approved route of administration is Topical (Cutaneous) application only, targeting the specific lesions. The procedure is defined by two mandatory sequential phases:

  • Phase 1: Drug Application and Incubation. The solution is prepared and applied directly to the lesions. A specific waiting period is required before light exposure:

    • Face or Scalp: 14 to 18 hours incubation.
    • Upper Extremities: 3 hours incubation with an occlusive dressing.
  • Phase 2: Photoactivation. Following incubation, the treated area is illuminated using the BLU-U Blue Light device. The required light dose is 10 J/cm^2, delivered over a continuous period of 1000 seconds (16 minutes and 40 seconds).

Frequency and Use Constraints

The treatment is limited to one application and illumination session per treatment region within an 8-week period. Retreatment may be considered 8 weeks after the initial session if lesions have not fully resolved.

Key Procedural Requirements

Constraint Detail
Preparation The solution must be used within 2 hours of being mixed.
Light Protection Treated skin must be shielded from sunlight and bright light for at least 40 hours after application.
Treatment Area Only one region (e.g., face or scalp) may be treated at a time.
Pediatric Use Safety and effectiveness have not been established for patients under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levulan

The clinical evaluation of Levulan Photodynamic Therapy (PDT) is based on formal research studies, including randomized controlled trials (RCTs), which are conducted to explore the measured response in the skin conditions under study. This research describes the observed patterns in patient populations under specific study conditions.


Evidence for Use in Actinic Keratoses (AKs)

Research exploring the activity of Levulan PDT has primarily involved large-scale, randomized, vehicle-controlled clinical trials. These studies were conducted on adult patients with minimally to moderately thick AK lesions on the face, scalp, or upper extremities. The designs of these pivotal studies were implemented to monitor outcomes in the research setting.

The main focus of these studies was to monitor and measure the clearance status of the targeted AK lesions. Studies reported measurements of higher complete clearance rates for the group receiving the Levulan solution and light combination compared to the group that received the inactive vehicle solution and light.

Long-Term Research and Durability of Response

Follow-up durations for the primary pivotal trials typically extended to 12 weeks post-treatment for initial clearance assessment, with some subsequent studies monitoring patients for longer periods, often 6 to 12 months. These studies explore the recurrence rate of the lesions that were initially cleared. However, long-term effects are not fully established beyond one year of follow-up for all patient groups and lesion types.

Evidence in Specific Patient Populations

The evidence base is specifically derived from studies on adult patients. Research currently provides limited information for the use of Levulan PDT in children under 18 years of age, where safety and effectiveness have not been established. Studies generally include older adults, and regulatory summaries have not demonstrated geriatric-specific issues in the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Levulan (FAQ)


Q: Is Levulan the name of the drug or the brand name of the treatment?

Levulan Kerastick is the brand name of the prescription product used in the procedure. The active substance in the solution is Aminolevulinic Acid (ALA), which is a precursor compound. Official documents classify ALA as the agent that enables the light-activated photodynamic therapy process.


Q: Is Levulan a type of chemotherapy?

Official regulatory documents classify Levulan as a Photodynamic Therapy (PDT) agent and a topical photochemotherapeutic agent. This means it uses a chemical and light to locally destroy abnormal cells. However, it is a localized, non-systemic treatment and is not considered a traditional systemic chemotherapy.


Q: How is Levulan different from other topical skin treatments?

Levulan is distinguished because it functions as a photosensitizer precursor for a two-stage procedure. Its therapeutic effect relies on a chemical reaction that is activated only when the skin is subsequently exposed to light from a specific device. Most other topical treatments do not require this mandatory light-activation step.


Q: How long does the Levulan treatment session usually last?

The entire treatment is defined by two required phases according to the official administration protocol. The first phase, drug application and incubation, lasts between 3 to 18 hours depending on the treatment area. The second phase, blue light illumination, lasts for a continuous period of 16 minutes and 40 seconds.


Q: What happens if the skin is not exposed to light after Levulan is applied?

The drug is converted into its active photosensitive form by the cells, but its therapeutic action only occurs when it is exposed to the blue light. If the light treatment is missed or delayed, official guidance specifies continued strict avoidance of sunlight and bright indoor light for at least 40 hours after the solution was first applied.


Q: What kind of interactions can Levulan have with my daily moisturizer?

Official instructions advise that the skin must be clean and free of all makeup, moisturizers, and sunscreens before the Levulan solution is applied for incubation. Official resources describe that moisturizers are typically applied to the treated area after the light treatment phase is complete.


Q: Can I use other topical medications with Levulan?

The official labeling documents a risk of additive phototoxicity when used with other photosensitizing topical or systemic medications. Official resources indicate that resuming prescribed or anti-aging topical products is often suggested only after the skin has healed, with some sources mentioning at least a one-week wait.


Q: Are the results from Levulan permanent?

Official research studies track the effectiveness by measuring the initial clearance rate of lesions. These studies also follow the recurrence rate of cleared lesions for up to one year after treatment. Regulatory documents do not use the term 'permanent' when describing the durability of the response.


Q: Why is blue light often used instead of other colors of light with Levulan?

The mechanism of action requires the activation of the photosensitive compound Protoporphyrin IX (PpIX) that accumulates in the target cells. Blue light is specified in the official protocol because its wavelength is effective at activating this specific photosensitizer to initiate the therapeutic destruction of the targeted cells.


Q: Is Levulan treatment considered cosmetic or medical?

Levulan Kerastick is regulated as a prescription medicine with a specific medical purpose. It is FDA-approved for the treatment of actinic keratoses (AKs), which are precancerous skin lesions caused by sun damage. The treatment is therefore classified as a medical intervention.


Q: Can I drive home after receiving Levulan photodynamic therapy?

The official labeling includes a warning for a rare but serious side effect known as a transient amnestic episode (temporary memory problem) following blue light exposure. Due to this potential side effect, and the need to follow light avoidance protocols, caution is advised regarding driving or operating machinery immediately after the procedure.

--UNSAFE: Driving/Caution Statement

Q: Is the photodynamic therapy procedure with Levulan painful?

According to patient information and clinical trial data, most patients will experience local sensations during the blue light illumination phase. These sensations include tingling, stinging, prickling, or burning of the treated skin, which are typically temporary and improve once the light treatment is finished.


Q: Can Levulan cause scarring?

The official safety profile for the drug, which lists common and rare adverse reactions, does not list scarring as a reported side effect of the treatment. Some patient-focused resources describe the treatment as one that is associated with low risk of scarring.


Q: How many treatments are typically needed?

The treatment is limited to one application and illumination session per region within an 8-week period. While retreatment is permitted if lesions have not fully resolved after 8 weeks, clinical data suggests that many patients are assessed for lesion clearance following 1 to 2 in-office treatments.


Q: Does Levulan treatment hurt more on certain parts of the body?

Clinical data collected during trials indicate that the frequency and intensity of some common local adverse reactions, such as stinging or burning, may be different across various treatment sites. The most commonly treated areas are the face, scalp, and upper extremities.


Q: Can Levulan be used on mucous membranes?

Official regulatory documents strictly approve the medication for Topical Use Only on the skin lesions of the face, scalp, and upper extremities. It is not approved for use on mucous membranes, the eyes, or other non-cutaneous areas.


Q: What should I do if my skin has a severe reaction after Levulan?

In the event of a severe or unusual reaction, such as a temporary memory problem or severe skin changes, official patient instructions state that the appropriate step is to immediately contact a healthcare provider. They also advise reporting side effects to the regulatory agencies, such as the FDA.


Q: Can Levulan be used to treat sun damage?

Levulan is officially approved for the treatment of actinic keratoses (AKs). These lesions are defined as rough, scaly patches on the skin that are a direct result of chronic sun exposure.


Q: Can I wear makeup immediately after the Levulan treatment?

Patient resources advise that it may be possible to apply makeup after the treatment, but only if there are no open areas or breaks in the skin. Official patient resources indicate that makeup is typically applied after the treatment, provided there are no open areas or breaks in the skin.


Q: How soon after the procedure can I return to work or school?

Due to the need for strict light avoidance for 40 hours after the drug application, patients are typically advised to stay indoors during this period. Patients are often advised they may be able to resume work or school activities within 24 to 48 hours after the photodynamic therapy is completed.


Q: What happens if I forget to wash off the Levulan after the application time?

The solution is designed to be absorbed into the target cells during the incubation period. Patient instructions state that the treated area should be gently rinsed and patted dry just before the blue light treatment. Official instructions indicate that the face should not be washed between the application and the light treatment steps.


Q: Is the light source used in the procedure dangerous?

The light device (BLU-U) is described in regulatory documents as a low intensity blue light device that is designed to provide only the fixed, required amount of light to activate the solution. Protective eyewear is provided and must be worn during the treatment to ensure safety.


Q: Has Levulan been studied in people with darker skin tones?

Official regulatory documents include a warning that patients with darker skin that tends to turn brown or discolor with exposure to light or laser treatments may not be suitable candidates for the treatment. The evidence base is not fully documented across all skin phototypes.


Q: Is Levulan the only aminolevulinate drug approved for skin conditions?

Levulan's active ingredient is Aminolevulinic Acid (ALA) and is one of the topical photochemotherapeutic agents approved for actinic keratoses. Related regulatory documents mention other ALA-based products used in similar Photodynamic Therapy protocols.


Q: Is Levulan used only by dermatologists?

The official prescribing information states that the product is a prescription medicine that must be applied in a doctor's office and used by a qualified healthcare provider only. It does not restrict the procedure exclusively to dermatologists.


Q: Is the redness after the procedure a sign that the treatment is working?

Redness (erythema) and swelling are officially described as expected, very common adverse reactions of the treatment. Clinical data indicates the intensity of this local reaction is often related to the level of underlying sun damage in the treated skin.

How should Levulan be stored and disposed of?

How to Store and Dispose of Levulan Kerastick

Storage and disposal requirements for Levulan Kerastick (aminolevulinic acid HCl) topical solution are strictly defined in the official regulatory labeling.

Storage Conditions

The unactivated applicator must be stored at Controlled Room Temperature, which is maintained below 25 C (below 77 F). It is mandatory to protect the product from freezing and to keep the applicator in its protective cardboard sleeve and cap to shield the components from damage.

Stability and Disposal

The chemical stability of the solution is highly time-sensitive after the internal components are mixed. The solution must be used immediately following preparation (dissolution). If the application of the solution is not completed within 2 hours of activation, the applicator must be discarded. All unused or expired product must be disposed of in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levulan found in:

A-Z Index: